Opus Genetics, Inc. financial data

Symbol
IRD on Nasdaq
Industry
Pharmaceutical Preparations
Location
37000 Grand River Ave., Suite 120, Farmington Hills, MI
State of incorporation
DE
Fiscal year end
December 31
Former names
Ocuphire Pharma, Inc. (to 10/22/2024), REXAHN PHARMACEUTICALS, INC. (to 11/9/2020), CORPORATE ROAD SHOW DOT COM INC (to 4/29/2005), FERRARO FRANK (to 4/29/2003)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 950 % -18%
Debt-to-equity 11.8 % +24.6%
Return On Equity -63.6 % -197%
Return On Assets -56.9 % -195%
Operating Margin -352 % -792%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.6M shares +39.5%
Common Stock, Shares, Outstanding 26.2M shares +15.9%
Entity Public Float 89.2M USD +140%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 26.1M shares +21.9%
Weighted Average Number of Shares Outstanding, Diluted 26.1M shares +16.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.38M USD -85.4%
General and Administrative Expense 14.2M USD +32.3%
Operating Income (Loss) -29.5M USD -201%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -27.2M USD -194%
Income Tax Expense (Benefit) -2K USD -101%
Net Income (Loss) Attributable to Parent -27.2M USD -195%
Earnings Per Share, Basic -1.08 USD/shares -174%
Earnings Per Share, Diluted -1.07 USD/shares -175%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.6M USD -13.5%
Accounts Receivable, after Allowance for Credit Loss, Current 1.86M USD -81.7%
Other Assets, Current 86K USD +68.6%
Assets, Current 40.4M USD -25.5%
Property, Plant and Equipment, Net 0 USD -100%
Assets 40.4M USD -25.5%
Accounts Payable, Current 844K USD -55.3%
Employee-related Liabilities, Current 410K USD -12.8%
Accrued Liabilities, Current 5.17M USD +168%
Liabilities, Current 6.09M USD +55.8%
Liabilities 6.09M USD +55.8%
Retained Earnings (Accumulated Deficit) -104M USD -35.5%
Stockholders' Equity Attributable to Parent 34.3M USD -31.8%
Liabilities and Equity 40.4M USD -25.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.72M USD -56.8%
Net Cash Provided by (Used in) Financing Activities 2.38M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 125M shares +66.7%
Common Stock, Shares, Issued 26.2M shares +15.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36.6M USD -13.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 20.1M USD +13.3%
Deferred Tax Assets, Gross 20.1M USD +9.43%
Depreciation 3K USD -25%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27.2M USD -195%
Property, Plant and Equipment, Gross 25K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 12.8M USD -2.35%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 138M USD +8.83%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Share-based Payment Arrangement, Expense 3.28M USD +1.71%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%